Renal Toxicity Associated With Antiretroviral Therapy

REFERENCES

• Winston J, Deray G, Hawkins T, Szczech L, Wyat C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis. 2008;47:1449–1457.
   PubMed Web of Science ®Google Scholar
• Cooper RD, ToneIli M. Renal disease associated with antiretroviral therapy in the treatment of HIV. Nephron Clin Pract. 2011118:c262–c268.
   Google Scholar
• Atta MG, Lucas GM, Fine DM. HIV-associated nephropa-thy: epidemiology, pathogenesis, diagnosis and manage-ment. Expert Rev Anti Infect Ther. 2008;6:365–371.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Lundgren JD, Neaton JD, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Wyatt C, Szczech L, et al. Interruption of anti-retroviral therapy is associated with increased plasma cystatin C. AIDS. 2009;23:71–82.
   PubMed Web of Science ®Google Scholar
• Kalayjian RC, Franceschini N, Gupta SK, et al. Suppres-sion of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22:481–487.
   PubMed Web of Science ®Google Scholar
• Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis. 2008;46:1271–1281.
   PubMed Web of Science ®Google Scholar
• Deeks SG. HIV infection, inflammation, immunosenes-cence, and aging. Annu Rev Med. 2011;62:141–155.
   PubMed Web of Science ®Google Scholar
• Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010;7:4–10.
   PubMedGoogle Scholar
• Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Asso-ciation of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585.
   PubMed Web of Science ®Google Scholar
• Winston JA. HIV and CKD epidemiology. Adv Chronic Kid-ney Dis. 2010;17:19–25.
   PubMed Web of Science ®Google Scholar
• Kalayjian RC. Renal issues in HIV infection. Curr HIV/AIDS Rep. 2011;8:164–171.
   PubMedGoogle Scholar
• Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis [published online ahead of print March 23,2012]. BMC Public Health.
   Google Scholar
• Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5:563–573.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
   Google Scholar
• European AIDS Clinical Society. Guidelines. Version 6.0. October 2011. http://www.europeanaidsclinicalsociety.org.
   Google Scholar
• Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011: 354908. Epub 2011 Jun 7.
   Google Scholar
• Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 201157: 773–780.
   Google Scholar
• Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22:99–103.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254.
   PubMed Web of Science ®Google Scholar
• Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010;53:62–69.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clear-ance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular fil-tration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667–1678.
   PubMed Web of Science ®Google Scholar
• Déti EK, Thiébaut R, Bonnet F, et al. Prevalence and fac-tors associated with renal impairment in HIV-infected patients, ANRS CO3 Aquitaine Cohort, France. HIV Med. 2010;11:308–317.
   PubMed Web of Science ®Google Scholar
• Tordato F, Cozzi Lepri A, Cicconi P, et al. Evaluation of glo-merular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12:4–13.
   PubMed Web of Science ®Google Scholar
• Calza L, Trapani F, Tedeschi S, et al. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients. Scand J Infect Dis. 201143: 656–660.
   Google Scholar
• Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496–505.
   PubMed Web of Science ®Google Scholar
• Scherzer R, Estrella M, Yongmei Li, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection [published online ahead of print February 4,2012]. AIDS.
   Web of Science ®Google Scholar
• Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23:1971–1975.
   PubMed Web of Science ®Google Scholar
• Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547–1556.
   PubMed Web of Science ®Google Scholar
• Dejesus E, Young B, Morales-Ramirez JO, et al. Simplifi-cation of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir diso-proxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 2009;51:163–174.
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized com-parison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55:49–57.
   PubMed Web of Science ®Google Scholar
• Martinez E, Arranz JA, Podzamczer D, et al. A simplifica-tion trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290–297.
   PubMed Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus rito-navir or efavirenz as part of a three-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011154: 445–456.
   Google Scholar
• Post FA, Wyatt CM, Mocroft A. Biomarkers of impaired renal function. Curr Opin HIV AIDS. 2010;5:524–530.
   PubMed Web of Science ®Google Scholar
• Hall AM, Edwards SG, Lapsley M, et al. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009;54: 1034–1042.
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomeru-lar function in HIV patients treated with tenofovir. AIDS. 2009;23:689–696.
   PubMed Web of Science ®Google Scholar
• Kinai E, Hanabusa H. Progressive renal tubular dysfunc-tion associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009;25:387–394.
   PubMed Web of Science ®Google Scholar
• Calmy A, Fux CA, Norris R, et al. Low bone mineral den-sity, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200:1746–1754.
   PubMed Web of Science ®Google Scholar
• Gatanaga H, Tachikawa N, Kikuchi Y, et al. Urinary beta-2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2006;22:744–748.
   PubMed Web of Science ®Google Scholar
• Jaafar A, Séronie-Vivien S, Malard L, Massip P, Chatelut E, Tack I. Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. AIDS. 2009;23: 257–259.
   PubMed Web of Science ®Google Scholar
• Woodward CL, Hall AM, Williams IG, et al. Tenofovir-asso-ciated renal and bone toxicity. HIV Med. 2009;10:482–487.
   PubMed Web of Science ®Google Scholar
• Horizon AA, Joseph RJ, Liao Q, Ross ST, Pakes GE. Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. HIV AIDS (Auckl). 2011;3: 53–59.
   PubMedGoogle Scholar
• Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40: 1194–1198.
   PubMed Web of Science ®Google Scholar
• Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, Emery S. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 2006;7:105–111.
   PubMed Web of Science ®Google Scholar
• Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular fil-tration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165–1173.
   PubMed Web of Science ®Google Scholar
• Young B, Buchacz K, Baker RK, et al. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Out-patient Study. J Int Assoc Physicians AIDS Care (Chic III). 2007;6:178–187.
   PubMedGoogle Scholar
• Goicoechea M, Liu S, Best B, et al. Greater tenofovir-asso-ciated renal function decline with protease inhibitor-based versus nonnucleoside reverse transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102–108.
   PubMed Web of Science ®Google Scholar
• Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10:329–336.
   PubMed Web of Science ®Google Scholar
• Overton ET, Nurutdinova D, Freeman J, Seyfried W, Mondy KE. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active anti-retroviral therapy. HIV Med. 2009;10:343–350.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Ganesan A, Teneza-Mora N, et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010;24:353–360.
   PubMed Web of Science ®Google Scholar
• Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir diso-proxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139:313–320.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743–746.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21: 1273–1281.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir diso-proxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47:74–78.
   PubMed Web of Science ®Google Scholar
• O'Donnell EP, Scarsi KK, Darin KM, Gerzenshtein L, Postelnick MJ, Palella FJ. Low incidence of renal impair-ment observed in tenofovir-treated patients. J Antimicrob Chemother 201166: 1120–1126.
   Google Scholar
• Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopi-navir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83:265–272.
   PubMed Web of Science ®Google Scholar
• Atazanavir (Reyataz) capsules [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2007.
   Google Scholar
• Darunavir (Prezista) tablets [prescribing information]. Bridgewater, NJ: Tibotec, Inc; 2007.
   Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53:323–332.
   PubMed Web of Science ®Google Scholar
• Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679–1688.
   PubMed Web of Science ®Google Scholar
• Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS. 2007;21:1431–1439.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Sayre JR, Flaherty JF, Chen SS, Kaul S, Cheng AK. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin PharmacoL 2005;45:1360–1367.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szc-zech LA, Kalayjian RC. The effects of HIV type-1 viral sup-pression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir Ther 2009;14:543–549.
   PubMed Web of Science ®Google Scholar
• Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'Agati VD. Adefovir nephrotoxicity: possible role of mito-chondrial DNA depletion. Hum PathoL 200132: 734–740.
   Google Scholar
• Birkus G, Hitchcock JM, Cihlar T. Assessment of mitochon-drial toxicity in human cells treated with tenofovir: compari-son with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716–723.
   PubMed Web of Science ®Google Scholar
• Cihlar T, LaFlamme G, Fisher R, et al. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: charac-terization of renal transport and accumulation. Antimicrob Agents Chemother 2009;53:150–156.
   PubMed Web of Science ®Google Scholar
• Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int. 2010;78:1060–1063.
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofo-vir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89:513–519.
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest. 201191: 852–858.
   Google Scholar
• Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78: 1171–1177.
   PubMed Web of Science ®Google Scholar
• Maggi P, Montinaro V, Ballacosa C, et al. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care STDS. 2012;26:5–11.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, D'Avolio A, et al. Impair-ment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24:1064–1066.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194:1481–1491.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predic-tors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108–e116.
   Web of Science ®Google Scholar
• Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011204: 145–153.
   Google Scholar
• Weyer K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010;55:78–81.
   PubMed Web of Science ®Google Scholar
• Campbell LJ, Hamzah L, Post FA. Is tenofovir-related renal toxicity incompletely reversible? J Acquir Immune Defic Syndr 2011;56:e95.
   PubMedGoogle Scholar
• Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS. 2005;19: 844–845.
   PubMed Web of Science ®Google Scholar
• Morris AA, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS. 200115: 140–141.
   Google Scholar
• Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52:296–297.
   PubMed Web of Science ®Google Scholar
• Krishnan M, Nair R, Haas M, Atta MG. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis. 2000;36:1075–1078.
   PubMed Web of Science ®Google Scholar
• Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52:296–297.
   PubMed Web of Science ®Google Scholar
• Krishnan M, Nair R, Haas M, Atta MG. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis. 2000;36:1075–1078.
   PubMed Web of Science ®Google Scholar
• Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read. 2009;19:114–121.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Valentin MA, Daudon M, Mohand HA, Caby F, Katlama C. Efavirenz urolithiasis. AIDS. 2007;21:1992.
   PubMed Web of Science ®Google Scholar
• Wirth GJ, Teuscher J, Graf JD, Iselin CE. Efavirenz-induced urolithiasis. Urol Res. 2006;34:288–289.
   PubMed Web of Science ®Google Scholar
• Angel-Moreno-Maroto A, Suarez-Castellano L, Hernan-dez-Cabrera M, Perez-Arellano JL. Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. J Infect. 2006;52:e39–e40.
   Google Scholar
• Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD. HIV-associated renal diseases and highly active anti-retroviral therapy-induced nephropathy. Clin Infect Dis. 2006;42:1488–1495.
   PubMed Web of Science ®Google Scholar
• Daugas E, Rougier JP, Hill G. HAART-related nephrop-athies in HIV-infected patients. Kidney Int. 2005;67: 393–403.
   PubMed Web of Science ®Google Scholar
• Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119–125.
   PubMed Web of Science ®Google Scholar
• Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med. 2002;162:1493–1501.
   PubMed Web of Science ®Google Scholar
• De Araujo M, Seguro AC. Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity. Antivir Ther 2002;7:181–184.
   PubMed Web of Science ®Google Scholar
• Herman JS, Ives NJ, Nelson M, Gazzard BG, Easterbrook PJ. Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 200148: 355–360.
   Google Scholar
• Casado JL, Moreno A, Sabido R, et al. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials. 2000;1: 13–19.
   PubMedGoogle Scholar
• Bochet MV, Jacquiaud C, Valentin MA, Katlama C, Deray G. Renal insufficiency induced by ritonavir in HIV-infected patients. Am J Med. 1998;105:457.
   PubMed Web of Science ®Google Scholar
• Green ST, McKendrick MW, Schmid ML, Mohsen AH, Prakasam SF. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS. 1998;9:555.
   PubMed Web of Science ®Google Scholar
• Engeler DS, John H, Rentsch KM, Ruef C, Oertle D, Suter S. Nelfinavir urinary stones. J Urol. 2002;167:1384–1385.
   PubMed Web of Science ®Google Scholar
• Doco-Lecompte T, Garrec A, Thomas L, Trechot P, May T, Rabaud C. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS. 2004;18:705–706.
   PubMed Web of Science ®Google Scholar
• Important information about Lexiva (fosamprenavir calcium) tablets and oral suspension. US Food and Drug Administration. April 12, 2009. www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm192905.htm.
   Google Scholar
• Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis. 2007; 45:e105-el 08.
   Web of Science ®Google Scholar
• Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Event Reporting System. AIDS. 2007;21:1215–1218.
   PubMed Web of Science ®Google Scholar
• Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis. 2004;44:e81–e84.
   Web of Science ®Google Scholar
• Schmid S, Opravil M, Moddel M, et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch. 2007;450:665–670.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equa-tion to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/ emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr. 201259: 18–24.
   Google Scholar
• Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348: 2175–2185.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Gottlieb MS, Gathe JO Jr, Greenberg ML, Guittari CJ, Zolopa AR. Safety and efficacy of enfu-virtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. Antimicrob Agents Chemother. 2008;52:4315–4319.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for pre-viously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–1441.
   PubMed Web of Science ®Google Scholar
• Gatell JM, Katlama C, Grinsztejn B, et al. Long-term effi-cacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase ll study. J Acquir Immune Defic Syndr. 2010;53:456–463.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Balk E, et al. National Kidney Founda-tion practice guidelines for chronic kidney disease: evalu-ation, classification, and stratification. Ann Intern Med. 2003;139:137–147.
   PubMed Web of Science ®Google Scholar
• Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW, Proko-powicz D, Rogalska M, Parfieniuk A. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir Ther 2006;11:641–645.
   PubMed Web of Science ®Google Scholar
• Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodefi-ciency virus infection: the FRAM study. Arch Intern Med. 2007;167:2213–2219.
   PubMed Web of Science ®Google Scholar
• Bonjoch A, Bayés B, Riba J, et al. Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antivir Res. 2010;88:347–354.
   PubMed Web of Science ®Google Scholar
• Vrouenraets SM, Fux CA, Wit FW, et al. A comparison of measured and estimated glomerular filtration rate in suc-cessfully treated HIV-patients with preserved renal func-tion. Clin NephroL 2012;77:311–320.
   PubMed Web of Science ®Google Scholar
• van Griensven J, Sopheak T, Koole O, Verpooten GA, Lynen L. Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used. J Acquir Immune Defic Syndr 2011;57:e21–e22.
   Web of Science ®Google Scholar
• Vrouenraets SM, Fux CA, Wit FW, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS. 201125: 2149–2155.
   Google Scholar
• Maggi P, Bartolozzi D, Bonfanti P, et al. Renal complica-tions in HIV disease: between present and future. AIDS Rev. 2012;14:37–53.
   PubMed Web of Science ®Google Scholar